FORT WORTH, Texas, Dec. 1 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc. a rapidly growing provider of specialty medical products, announced today that further positive case study data on CellerateRx(R), the core product of the Wound Care Innovations, LLC operating subsidiary, was released at the recent 6(th) Annual High Risk Diabetic Foot Conference for VA Podiatrists and Healthcare Professional in Tempe, AZ.
“We were delighted to be a part of this exciting conference. Dr. Jane Fore is a leading authority in the wound care field, and we welcome her findings,” states Cathy Bradshaw, President of Wound Care Innovations. “This was the largest meeting that they have held and included leading experts in a variety of disciplines from within as well as external to the VA. Diabetic wounds and the incidence of amputations is a serious issue in healthcare. This conference focused on the principles of amputation prevention both in the VA and Federal Service and the non-government sectors. Our product successfully addresses a five billion dollar worldwide market.”
CellerateRx(R) is FDA cleared for acute and chronic wounds which include but are not limited to: diabetic ulcers, venous stasis ulcers, ulcers due to arterial insufficiency, pressure ulcers stages I-IV, surgical wounds, traumatic wounds, superficial wounds, and 1(st) and 2(nd) degree burns. It comes in two forms, a powder which is about 95% collagen, and a gel which is about 65% collagen, and contains no additives or synthetics. CellerateRx(R) is manufactured in the United States. “Several independently run evidence-based studies have certified our product’s value, and the overwhelmingly positive data can now be accessed at www.woundmanagementtechnologies.com ,” said Cathy Bradshaw, President of Wound Care Innovations, the division that markets CellerateRx.
For Wound Management Technologies Shareholder Information please call 954-357-0614.
“Safe Harbor” Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products in development are “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company’s SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
Wound Management Technologies, Inc.
